AstraZeneca has achieved another clinical milestone with tozorakimab, its investigational chronic obstructive pulmonary disease therapy, as the drug successfully met its primary objective in a third Phase III study.
Results from the MIRANDA study revealed that tozorakimab achieved a statistically meaningful decrease in the yearly rate of moderate-to-severe COPD exacerbations when compared against placebo. Importantly, these benefits were observed consistently across both the primary cohort of former smokers and the expanded patient group that included individuals who continue to smoke.
Study participants administered themselves either tozorakimab 300mg or placebo bi-weekly while maintaining their current standard-of-care medications. The trial specifically recruited individuals who continued experiencing exacerbations despite ongoing treatment with inhaled therapies.
The drug’s safety characteristics aligned with previous clinical studies, and investigators reported that tozorakimab was generally well accepted by patients.
MIRANDA represents the third positive Phase III readout for tozorakimab. Earlier this year in March, AstraZeneca revealed favorable outcomes from two additional Phase III studies — OBERON and TITANIA — which evaluated the medication using a monthly administration schedule.
By contrast, MIRANDA utilized bi-weekly dosing, providing the pharmaceutical company with comprehensive evidence across multiple treatment frequencies.
Tozorakimab represents a potentially first-in-class monoclonal antibody designed to inhibit interleukin-33, an inflammatory protein. This novel mechanism distinguishes it from conventional inhaled COPD medications currently available.
Frank Sciurba, a professor at the University of Pittsburgh and chief investigator of the LUNA program, said the results “add to the growing body of evidence that indicates tozorakimab delivered meaningful clinical benefits for COPD patients who urgently need new treatment options.”
Chronic obstructive pulmonary disease impacts approximately 400 million individuals worldwide and ranks as the third most common cause of mortality globally. Despite standard inhaled treatment protocols, more than half of all patients continue suffering from exacerbations — representing a substantial unmet medical need that tozorakimab aims to address.
AstraZeneca intends to file the MIRANDA study data with health regulatory agencies. Additionally, the pharmaceutical company will share detailed findings at a forthcoming medical conference, although the specific venue and timing have not yet been disclosed.
In addition to COPD development, tozorakimab is currently under evaluation in Phase III clinical programs for severe viral lower respiratory tract infections and in Phase II studies targeting asthma.
The MIRANDA trial enrolled patients across the full spectrum of blood eosinophil levels and all degrees of lung function impairment, potentially expanding the eligible patient population for future treatment.
AstraZeneca has not provided specific timing regarding when regulatory filings will be submitted.
The post AstraZeneca (AZN) Stock: Tozorakimab Achieves Phase III COPD Success in MIRANDA Study appeared first on Blockonomi.
